Resmed (RSMDF) Payables (2010 - 2026)

Resmed has reported Payables for 17 years, with the latest figure at $533.2 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 129.38% year-over-year to $533.2 million; the trailing twelve-month figure through Mar 2026 stood at $533.2 million (up 129.38% YoY), and the FY2025 full-year result was $288.1 million, up 16.33% from the prior year.
• Payables for Q1 2026 stood at $533.2 million, up from $510.3 million in the prior quarter.
• The five-year high for Payables was $533.2 million in Q1 2026, with the low at $160.7 million in Q2 2023.
• Historically, Payables has averaged $263.2 million across 5 years, with a median of $212.3 million in 2023.
• Annual changes were most pronounced in 2023 — Payables slipped 5.03% — and 2026, when it jumped 129.38%.
• Resmed's Payables stood at $205.9 million in 2022, then grew by 3.1% to $212.3 million in 2023, then gained by 8.44% to $230.2 million in 2024, then jumped by 121.66% to $510.3 million in 2025, then advanced by 4.49% to $533.2 million in 2026.
• The last three Payables figures came in at $533.2 million (Q1 2026), $510.3 million (Q4 2025), and $526.7 million (Q3 2025), per Business Quant data.